These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31082272)

  • 21. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Stoen E; Kagihara J; Shagisultanova E; Fisher CM; Nicklawsky A; Kabos P; Borges VF; Diamond JR
    Breast Cancer Res Treat; 2021 Jun; 187(3):883-891. PubMed ID: 33625615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.
    Soto-Perez-De-Celis E; Loh KP; Baldini C; Battisti NML; Chavarri-Guerra Y; De Glas NA; Hsu T; Hurria A
    Expert Opin Investig Drugs; 2018 Oct; 27(10):787-801. PubMed ID: 30196727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.
    Esposito A; Viale G; Criscitiello C; Curigliano G
    Expert Rev Clin Pharmacol; 2019 Jan; 12(1):9-16. PubMed ID: 30466330
    [No Abstract]   [Full Text] [Related]  

  • 27. Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.
    Copeland AC; Anders CK
    Oncology (Williston Park); 2018 Oct; 32(10):483-7. PubMed ID: 30334236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neratinib in the early-stage/extended adjuvant breast cancer patient.
    O'Shaughnessy JA; Isaacs C; O'Regan R
    Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
    Martin M; López-Tarruella S
    Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neratinib in HER2-Positive Breast Cancer Patients.
    Paranjpe R; Basatneh D; Tao G; De Angelis C; Noormohammed S; Ekinci E; Abughosh S; Ghose R; Trivedi MV
    Ann Pharmacother; 2019 Jun; 53(6):612-620. PubMed ID: 30607980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
    Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the management of HER2-positive early breast cancer.
    Baselga J; Coleman RE; Cortés J; Janni W
    Crit Rev Oncol Hematol; 2017 Nov; 119():113-122. PubMed ID: 29042085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.
    Rocca A; Andreis D; Fedeli A; Maltoni R; Sarti S; Cecconetto L; Pietri E; Schirone A; Bravaccini S; Serra P; Farolfi A; Amadori D
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1647-63. PubMed ID: 26307328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.